Cancer is a scourge on society. One in two Americans will be diagnosed with cancer during their lifetime and one in five will die. The five-year cancer survival rates approach 90% when diagnosed in the earliest stages of the disease versus just 10% in the latest stages.
We believe it doesn’t have to be this way.
Assembled a deep clinical evidence library with data collected from more than 1,200 subjects
More than 20 premier cancer institutions around the world participated in our clinical trials
IONIQ's ProLung Test was awarded “Breakthrough Device Designation” by US FDA for its life-enhancing potential
Robust, growing intellectual portfolio of patents and know-how
Salt Lake City, UT, May 10, 2022 – IONIQ Sciences is humbled to be recognized with three separate awards from ‘Global 100‘ especially during ‘Lung Cancer Hope Month.’ These three awards and earlier designation by the US FDA as a ‘Breakthrough Device‘ is further validation of our growing
Salt Lake City, UT, May 2, 2022 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”) was honored to welcome Salt Lake City Mayor Mendenhall to its office today. During the Mayor’s visit, Michael Garff, IONIQ COO, shared how the Company is developing a Multi-Cancer Screen to help physicians
Salt Lake City, UT, March 17, 2022 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”) announced today that it has hired Edison Group, a leading investor relations and research firm, to assist with its investor relations program. Edison Group, established in 2003, is an investor relations, investor
